Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lm-LLO-CD105A
- Development stage
- Preclinical
- Lead developer
- Advaxis
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Lm-LLO-CD105A (also known as ADXS31-171) is an investigational cancer vaccine consisting of a live-attenuated *Listeria monocytogenes* (Lm) bacterial vector engineered to secrete a fusion protein of truncated Listeriolysin O (tLLO) and the tumor-associated antigen CD105 (Endoglin). CD105 is a proliferation-associated antigen highly expressed on the endothelial cells of the tumor vasculature, making it a strategic target for anti-angiogenic immunotherapy. The Lm-LLO platform facilitates the delivery of the antigen directly into antigen-presenting cells, where it is processed and presented to stimulate a robust, polyfunctional CD8+ T-cell response. This immune response is designed to selectively destroy the tumor's blood supply, thereby inhibiting tumor growth and metastasis. While clinical development by Advaxis was terminated after Phase 1 trials in advanced solid tumors, the vaccine continues to be evaluated in preclinical research, particularly in combination with novel immunoadjuvants like ISG15.
- Other names
- Listeria monocytogenes-LLO-CD105ADXS31-171ADXS-31-171ADXS 31-171
02
Targets
CD105/MHC-I (Endoglin-derived peptide/Major Histocompatibility Complex class I complex)
Beyond the preview
Go deeper on Lm-LLO-CD105A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lm-LLO-CD105A.